Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis

被引：0
|
作者：
Calvo, V.
Ramirez, N.
Saura, C.
Vidal, M.
Velasco, A.
Llombart-Cussac, A.
Cortes-Funes, H.
Miles, D.
Baselga, J.
Cortes, J.
机构：
[1] Hosp Univ Princesa, Madrid, Spain
[2] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[3] Hosp Valle De Hebron, Barcelona, Spain
[4] Hosp Arnau Vilanova, Lleida, Spain
[5] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
[6] Mt Vernon Canc Ctr, Northwood, Middx, England
[7] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1043
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Bevacizumab related adverse events in patients affected by metastatic colorectal cancer: a meta-analysis
    Galfrascoli, Elena
    Garassino, Marina C.
    Cinquini, Michela
    Rossi, Antonio
    Manazza, Andrea
    Damia, Giovanna
    Farina, Gabriella
    Muserra, Gaetana
    PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 239 - 239
  • [22] Bevacizumab related adverse events in patients affected by metastatic colorectal cancer: a meta-analysis
    Galfrascoli, E.
    Cinquini, M.
    Rossi, A.
    Manazza, A.
    Damia, G.
    Banna, G.
    Tosoni, A.
    Tiseo, M.
    Farina, G.
    Garassino, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 343 - 343
  • [23] The risk of venous thromboembolic events in patients with inflammatory bowel disease: a systematic review and meta-analysis
    Arvanitakis, Konstantinos D.
    Arvanitaki, Alexandra D.
    Karkos, Christos D.
    Zintzaras, Elias A.
    Germanidis, Georgios S.
    ANNALS OF GASTROENTEROLOGY, 2021, 34 (05): : 680 - +
  • [24] Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies.
    Avina, Michelle
    Choi, Sally
    Rai, Sharan
    Choi, Hyon K.
    De Vera, Mary
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S617 - S618
  • [25] Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials
    Ma, Zhuo
    Sun, Ximu
    Zhang, Yi
    Li, Hao
    Sun, Dan
    An, Zhuoling
    Zhang, Yuhui
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (10) : 1757 - 1766
  • [26] Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
    Cortes, J.
    Calvo, V.
    Ramirez-Merino, N.
    O'Shaughnessy, J.
    Brufsky, A.
    Robert, N.
    Vidal, M.
    Munoz, E.
    Perez, J.
    Dawood, S.
    Saura, C.
    Di Cosimo, S.
    Gonzalez-Martin, A.
    Bellet, M.
    Silva, O. E.
    Miles, D.
    Llombart, A.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1130 - 1137
  • [27] VENOUS AND ARTERIAL THROMBOEMBOLIC RISK OF JAK INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Campanaro, F.
    Batticciotto, A.
    Zaffaroni, A.
    Donadini, M. P.
    Squizzato, A.
    Cappelli, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 734 - 734
  • [28] Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
    Poenou, Geraldine
    Toledano, Emmanuel
    Helfer, Helene
    Plaisance, Ludovic
    Happe, Florent
    Versini, Edouard
    Diab, Nevine
    Djennaoui, Sadji
    Mahe, Isabelle
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [29] Risk of venous thromboembolic events on antipsychotic drugs: a meta-analysis of observational studies
    Chapelle, C.
    Beyens, M. N.
    Quenet, S.
    Delavenne, X.
    Lacut, K.
    Mismetti, P.
    Laporte, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 75 - 76
  • [30] Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: A meta-analysis
    Sher, A. F.
    Chu, D.
    Wu, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345